
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
WASHC2A (WASH complex subunit 2A) encodes a component of the WASH complex that participates in endosomal protein localization. It has predicted phosphatidylinositol phosphate- and retromer-binding activities and is associated with the cytosol and nucleolus. WASHC2A contributes to membrane trafficking and endosomal organization through interactions with phosphoinositides and retromer-associated machinery.
The K-562 cell line was established by Lozzio and Lozzio in 1970 from the pleural effusion of a 53-year-old female patient with chronic myeloid leukemia (CML) in blast crisis. The cells carry the BCR-ABL1 e14-a2 (b3-a2) fusion gene and exhibit characteristics of myeloid leukemia cells, including hemoglobin production. K-562 is a human leukemia cell model widely used for studying CML biology, myeloid differentiation, hematopoietic signaling, and immune cell interactions, including applications as an in vitro target model in natural killer (NK) cell assays.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use






Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?